ACTRN12608000007336已完成未知
A prospective, randomised, controlled, cross-over study to evaluate the effects of orthokeratology versus conventional rigid gas permeable contact lens wear on the progression of myopia in children and adolescents.
Prof Helen Swarbrick0 个研究点目标入组 75 人开始时间: 2008年1月9日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 8 Years 至 16 Years（—）
- 性别
- All
入选标准
- •Participants will be required to have myopic refractive error between -1.00 and -4.00D at the time of study enrolment, evidence of progression of myopia over the previous 12 months, <0.75D refractive difference between the two eyes, <1.50D with-the-rule corneal astigmatism, and no against-the-rule astigmatism. Subjects must be of East Asian ethnicity, have good general and ocular health, and no history of rigid contact lens wear. Normal corneal topography, normal binocular function, and vision correctable to 6/9 (20/30) or better are also required for study enrolment.
排除标准
- •Potential subjects will not be enrolled if they show any contraindications for rigid contact lens wear, abnormal binocular function, anisometropia > 0.75D, ocular pathology or active ocular surface disease that would preclude contact lens wear.
研究者
相似试验
进行中（未招募）
1 期
A controlled, randomised, study investigating the pharmacokineticproperties (to see how active the study drug is in your blood and how long it takes for the study drug to get out of your blood) , surrogate efficacy and safety of Octafibrin compared to Haemocomplettan® P/ RiaSTAPTM in subjects with congenital fibrinogen deficiencyCongenital fibrinogen deficiency (afibrinogenaemia) defined as plasma fibrinogen activity and antigen at screening below detection limit (i.e. <20mg/dl)MedDRA version: 14.1Level: LLTClassification code 10052651Term: AfibrinogenaemiaSystem Organ Class: 100000004850EUCTR2011-002403-15-DEOCTAPHARMA AG22
进行中（未招募）
不适用
A controlled, randomised, study investigating thepharmacokinetic properties (to see how active the study drug is in your blood and how long it takes for the study drug to get out of your blood) ,surrogate efficacy and safety of Octafibrin compared toHaemocomplettan® P/ RiaSTAPTM in subjects with congenital fibrinogen deficiencyEUCTR2011-002403-15-ITOCTAPHARMA AG18
进行中（未招募）
不适用
A controlled, randomised, study investigating the pharmacokineticproperties (to see how active the study drug is in your blood and how long it takes for the study drug to get out of your blood) , surrogate efficacy and safety of Octafibrin compared to Haemocomplettan® P/ RiaSTAPTM in subjects with congenital fibrinogen deficiencycongenital fibrinogen deficiencyMedDRA version: 16.0Level: LLTClassification code 10052651Term: AfibrinogenaemiaSystem Organ Class: 100000004850EUCTR2011-002403-15-GBOCTAPHARMA AG18
进行中（未招募）
2 期
A clinical trial to study the efficacy And Safety Of Octafibrin Compared To Haemocomplettan® P/ Riastap� In Subjects With Congenital Fibrinogen Deficiency.CTRI/2013/09/003953Octapharma AG18
已完成
不适用
comparing normal breathing for 3 minutes and 8 deep breaths in 1 minute to achieve better oxygenation before giving general anaesthesiaCTRI/2017/05/008498P D Hinduja National Hospital and MRC270